Namely, the anti‐tumor efficacy of CAR‐engineered NK‐92 cells directed toward EpCAM and/or tumor‐specific antigens was evaluated on patient‐derived CRC organoids seeded on a Matrigel‐coated surface. Here, EPCAM is linked to neoplasm.